Fig. 1From: Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world studyPatient disposition. All numbers expressed are in thousands. *Excludes abatacept. †Based on MacLean’s positive predictive value of an administrative data-based algorithm for the identification of patients with RA [29]. b/tsDMARDs, biologic or targeted synthetic disease-modifying antirheumatic drugs; RA, rheumatoid arthritisBack to article page